

Physician Office Laboratory Testing

Medicaid & My Care Line of business

Purpose

This policy is intended to ensure correct provider reimbursement and serves only as a general resource regarding Molina Healthcare's reimbursement policy for the services described in this policy. It is not intended to address every aspect of a reimbursement situation, nor is it intended to impact care decisions. This policy was developed using nationally accepted industry standards and coding principles. In a conflict, federal and state guidelines, as applicable, and the member's benefit plans supersede the information in this policy. Also, to the extent of conflicts between this policy and the provider contract language, the Provider contract language will prevail. Coverage may be mandated by applicable legal requirements of a State, the Federal government or the Centers for Medicare and Medicaid Services (CMS). References included were accurate at the time of policy approval. If there is a state exception, please refer to the state exception table listed below.

Policy Overview

The services below are allowed in a physician's office, for all lines of business. All other lab testing must be referred to an In-Network Laboratory Provider that is a certified, full-service laboratory, offering a comprehensive test menu that includes routine, complex, drug, genetic testing and pathology. For more information about In-Network Laboratory Providers, please consult the Molina Provider Directory (https://providersearch.molinahealthcare.com/). For testing available through In-Network Laboratory Providers, or for a list of In-Network Laboratory Provider patient services centers, please reach out to the In-Network Laboratory Provider. Specimen collection is allowed in a physician's office and shall be compensated in accordance with your agreement with Molina Healthcare and applicable state and federal billing and payment rules and regulations.

Reimbursement Guidelines

The codes billed below are reimbursable when performed in a physician's office. Molina Healthcare retains the authority to deny, review, audit, and recoup claims based on medical necessity as outlined in the above policy.

| Code | Description |
|-------|---|
| 80047 | Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium, ionized (82330) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520) |
| 80048 | Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) |

| | | MOLINA® HEALTHCARE |
|---|-------|-----------------------|
| Г | 00050 | |

| | Comprehensive metabolic panel This panel must include the following: Albumin (92040) |
|-------|---|
| 80053 | Comprehensive metabolic panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphatase, alkaline (84075) Potassium (84132) Protein, total (84155) Sodium (84295) Transferase, alanine amino (ALT) (SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450) Urea nitrogen (BUN) (84520) |
| 80061 | Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478) |
| 80178 | Lithium |
| 80305 | Drug test(s), presumptive, any number of drug classes, any number of devices or |
| | procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service |
| 80306 | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service |
| 80307 | Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service |
| 80324 | Amphetamines; 1 or 2 |
| 80325 | Amphetamines; 3 or 4 |
| 80326 | Amphetamines; 5 or more |
| 80327 | Anabolic steroids; 1 or 2 |
| 80328 | Anabolic steroids; 3 or more |
| 80329 | Analgesics, non-opioid; 1 or 2 |
| 80330 | Analgesics, non-opioid; 3-5 |
| 80331 | Analgesics, non-opioid; 6 or more |
| 80332 | Antidepressants, serotonergic class; 1 or 2 |
| 80333 | Antidepressants, serotonergic class; 3-5 |
| 80334 | Antidepressants, serotonergic class; 6 or more |
| 80335 | Antidepressants, tricyclic and other cyclicals; 1 or 2 |
| 80336 | Antidepressants, tricyclic and other cyclicals; 3-5 |
| 80337 | Antidepressants, tricyclic and other cyclicals; 6 or more |
| 80338 | Antidepressants, not otherwise specified |
| 80339 | Antiepileptics, not otherwise specified; 1-3 |
| 80340 | Antiepileptics, not otherwise specified; 4-6 |
| 80341 | Antiepileptics, not otherwise specified; 7 or more |
| 80342 | Antipsychotics, not otherwise specified; 1-3 |
| 80343 | Antipsychotics, not otherwise specified; 4-6 |
| 80344 | Antipsychotics, not otherwise specified; 7 or more |
| 80345 | Barbiturates |
| 80346 | Benzodiazepines; 1-12 |
| 80347 | Benzodiazepines; 13 or more |
| 80348 | Buprenorphine |

| | OLINA® ALTHCARE |
|-------|------------------------|
| 80349 | Cannahinoids natural |

| 80349 | Cannabinoids, natural |
|-------|--|
| 80350 | Cannabinoids, synthetic; 1-3 |
| 80351 | Cannabinoids, synthetic; 4-6 |
| 80352 | Cannabinoids, synthetic; 7 or more |
| 80353 | Cocaine |
| 80354 | Fentanyl |
| 80355 | Gabapentin, non-blood |
| 80356 | Heroin metabolite |
| 80357 | Ketamine and norketamine |
| 80358 | Methadone |
| 80359 | Methylenedioxyamphetamines (MDA, MDEA, MDMA) |
| | |
| 80360 | Methylphenidate |
| 80361 | Opiates, 1 or more |
| 80362 | Opioids and opiate analogs; 1 or 2 |
| 80363 | Opioids and opiate analogs; 3 or 4 |
| 80364 | Opioids and opiate analogs; 5 or more |
| 80365 | Oxycodone |
| 80366 | Pregabalin |
| 80367 | Propoxyphene |
| 80368 | Sedative hypnotics (non-benzodiazepines) |
| 80369 | Skeletal muscle relaxants; 1 or 2 |
| 80370 | Skeletal muscle relaxants; 3 or more |
| 80371 | Stimulants, synthetic |
| 80372 | Tapentadol |
| 80373 | Tramadol |
| 80374 | Stereoisomer (enantiomer) analysis, single drug class |
| 80375 | Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 1-3 |
| 80376 | Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 4-6 |
| 80377 | Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 7 or more |
| 81000 | Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy |
| 81001 | Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy |
| 81002 | Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these |

constituents; non-automated, without microscopy

Urinalysis; qualitative or semiquantitative, except immunoassays

Urine pregnancy test, by visual color comparison methods

constituents; automated, without microscopy

Albumin; urine (eg, microalbumin), quantitative

Alcohol (ethanol); breath

Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these

Albumin; urine (eg, microalbumin), semiquantitative (eg, reagent strip assay)

81003

81005

81025

82043

82044

82075

| | MOLINA [®] |
|-------|---------------------|
| | HEALTHCARE |
| 00400 | |

| 82120 | Amines, vaginal fluid, qualitative |
|-------|--|
| 82247 | Bilirubin; total |
| 82248 | Bilirubin; direct |
| 82270 | Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection) |
| 82271 | Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources |
| 82272 | Blood, occult, by peroxidase activity (eg, guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening |

| 82565 Cr | holesterol, serum or whole blood, total reatinine; blood reatinine; other source reatinine; clearance |
|-----------|---|
| | reatinine; other source |
| 82570 Cr | , |
| | reatinine: clearance |
| | , |
| 82731 Fe | etal fibronectin, cervicovaginal secretions, semi-quantitative |
| 82947 GI | lucose; quantitative, blood (except reagent strip) |
| 82948 GI | lucose; blood, reagent strip |
| 82950 GI | lucose; post glucose dose (includes glucose) |
| 82951 GI | lucose; tolerance test (GTT), 3 specimens (includes glucose) |
| | lucose; tolerance test, each additional beyond 3 specimens (List separately in addition code for primary procedure) |
| | lucose, blood by glucose monitoring device(s) cleared by the FDA specifically for ome use |
| 83036 He | emoglobin; glycosylated (A1C) |
| 83051 He | emoglobin; plasma |
| 83655 Le | ead |
| 83721 Lip | poprotein, direct measurement; LDL cholesterol |
| 83735 Ma | agnesium |
| 83986 pF | H; body fluid, not otherwise specified |
| 83992 Ph | nencyclidine (PCP) |
| 84132 Pc | otassium; serum, plasma or whole blood |
| 84443 Th | nyroid stimulating hormone (TSH) |
| 84703 Go | onadotropin, chorionic (hCG); qualitative |
| 85007 Blo | ood count; blood smear, microscopic examination with manual differential WBC count |
| | ood count; blood smear, microscopic examination without manual differential WBC |
| 85013 Blo | ood count; spun microhematocrit |
| 85014 Blo | ood count; hematocrit (Hct) |
| 85018 Blo | ood count; hemoglobin (Hgb) |
| | ood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and utomated differential WBC count |
| | ood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) |
| 85032 Blo | ood count; manual cell count (erythrocyte, leukocyte, or platelet) each |

| MOLINA® |
|----------------|
| HEALTHCARE |

| | 1EALI II CARE |
|-------|--|
| 85049 | Blood count; platelet, automated |
| 85060 | Blood smear, peripheral, interpretation by physician with written report |
| 85576 | Platelet, aggregation (in vitro), each agent |
| 85610 | Prothrombin time; |
| 85651 | Sedimentation rate, erythrocyte; non-automated |
| 86308 | Heterophile antibodies; screening |
| 86318 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single- step method (eg, reagent strip); |
| 86328 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
| 86408 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen |
| 86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |

| 86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer |
|-------|--|
| 86580 | Skin test; tuberculosis, intradermal |
| 86592 | Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) |
| 86756 | Antibody; respiratory syncytial virus |
| 86769 | Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
| 87070 | Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates |
| 87172 | Pinworm exam (eg, cellophane tape prep) |
| 87205 | Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types |
| 87210 | Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps) |
| 87220 | Tissue examination by KOH slide of samples from skin, hair, or nails for fungi or ectoparasite ova or mites (eg, scabies) |
| 87270 | Infectious agent antigen detection by immunofluorescent technique; Chlamydia trachomatis |
| 87275 | Infectious agent antigen detection by immunofluorescent technique; influenza B virus |
| 87276 | Infectious agent antigen detection by immunofluorescent technique; influenza A virus |
| 87280 | Infectious agent antigen detection by immunofluorescent technique; respiratory syncytial virus |
| 87301 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41 |
| 87400 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Influenza, A or B, each |
| 87420 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; respiratory syncytial virus |

| MOLINA® |
|-------------------|
| HEALTHCARE |

| | <u> </u> | | |
|---|---|--|--|
| 87426 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) | | |
| Infectious agent antigen detection by immunoassay technique, (eg, enzyr immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluore immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative semiquantitative; severe acute respiratory syndrome coronavirus (eg, SAF SARS-CoV-2 [COVID-19]) and influenza virus types A and B | | | |
| 87430 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Streptococcus, group A | | |
| 87490 | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique | | |
| 87491 | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | | |
| 87502 | Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types | | |
| 87634 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory syncytial virus, amplified probe technique | | |
| 87635 | · · · · · · · · · · · · · · · · · · · | | |
| 87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique | | |
| 87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique | | |
| 87651 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique | | |
| 87800 | Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique | | |
| 87802 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group B | | |
| 87803 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Clostridium difficile toxin A | | |
| 87804 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza | | |
| 87806 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies | | |
| 87807 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; respiratory syncytial virus | | |
| 87808 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis | | |

| MOLINA ° |
|-------------------|
| HEALTHCARE |

| | ALIHCARE | | |
|---|--|--|--|
| 87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | | | |
| 87880 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | | |
| 87905 | Infectious agent enzymatic activity other than virus (eg, sialidase activity in vaginal fluid) | | |
| 88150 | Cytopathology, slides, cervical or vaginal; manual screening under physician supervision | | |
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision | | |
| Cytopathology, slides, cervical or vaginal; with manual screening and rescreening uphysician supervision | | | |
| 88155 Cytopathology, slides, cervical or vaginal, definitive hormonal evaluation (equindex, karyopyknotic index, estrogenic index) (List separately in addition to other technical and interpretation services) | | | |
| Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision | | | |
| 88165 | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision | | |
| Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision | | | |
| Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review unde physician supervision | | | |
| 88174 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision | | |
| 88175 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | | |



| ALIHCAKE |
|---|
| Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine Prostate, needle biopsy Prostate, TUR Salivary gland, biopsy Sinus, paranasal biopsy Skin, other than cyst/tag/debridement/plastic repair Small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) |
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry |
| Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen |
| Pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure) |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure |
| Bilirubin, total, transcutaneous |
| Crystal identification by light microscopy with or without polarizing lens analysis, tissue or any body fluid (except urine) |
| Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected |
| Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected |
| |

| MOLINA® |
|----------------|
| HEALTHCARE |

| IILALIIICARL | | | | |
|--------------|---|--|--|--|
| 0225U | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | | | |
| 0240U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected | | | |
| 0241U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenz B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected | | | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | | | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | | | |

| | | | | | • |
|---|----|------|---|------------------------------|----|
| | | | | OLINA | |
| | | | H | ALTHCARE Drug test(s), de | - |
| ١ | GC |)481 | | Drug test(s), de | ef |

| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | | |
|---------------|--|--|--|
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drugspecific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | | |
| Q0112 | All potassium hydroxide (koh) preparations | | |
| 81015 | Urinalysis; microscopic only | | |
| 80069 | Renal function panel This panel must include the following: Albumin (82040) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphorus inorganic (phosphate) (84100) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | | |
| 87591 | Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | | |
| 87650 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, direct probe technique | | |
| 87660 | Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique | | |
| 87661 | Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | | |
| 84436 | Thyroxine, Free | | |
| 84437 | Thyroxine, Requiring Elution | | |
| 84439 | Thyroxine, Free | | |
| 85095 | Bone Marrow ASP only | | |
| 85102 | Bone Marrow Biopsy Core | | |
| 85535 | Iron Stain | | |
| 81000-81005 | Urinalysis | | |
| 82043 - 82044 | Urine Microalbumin | | |
| 82270 - 82272 | Blood, Occult | | |
| 82565 - 82575 | Creatinine | | |
| 85025 - 85027 | CBC | | |
| 86140 - 86141 | C Reactive Protein | | |
| 88150 - 88155 | Pathology/Pap Smear | | |

| | IOLINA |
|---------------|--|
| HE | ALTHCARE |
| 88164 - 88167 | Pathology/Pap Smear |
| 88174 - 88175 | Pathology/Pap Smear |
| 88312 - 88313 | Pathology |
| 88331 - 88332 | Pathology Consultation, during surgery |

<u>CODING DISCLAIMER.</u> Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

Supplemental Information

Definitions

| Term | Definition |
|------|---|
| CMS | the Centers for Medicare & Medicaid Services. It is a federal agency within the United States Department of Health and Human Services that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program (CHIP), and health insurance portability standards. |

State Exceptions

| State | Exception |
|-------|-----------|
| | |

Documentation History

| Туре | Date | Action |
|--------------|------------|---------------------------------------|
| Published | 9/15/23 | New |
| Revised Date | 11-13-24 | Coding Updates |
| Revised date | 03/31/2025 | Effective date for Ohio is 05/01/2025 |

References

This policy was developed using https://providersearch.molinahealthcare.com/